Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: Damon Pham who wrote (697)	9/13/1998 10:26:00 PM
From: M.A. Caccavo	Read Replies (1) \| Respond to of 849

for what it is worth... a few of the insiders bought shares recently.

To: Damon Pham who wrote (697)	10/7/1998 8:41:00 AM
From: Marty Lee	Read Replies (1) \| Respond to of 849

Match with Lab Corp sounds great but.. I believe that Matritech is being run more like a lab clinic than a public company. Matritech maintains and develops a costly portfolio of NMP solutions. Their development alone cost millions. Selling, general and administrative costs continue to outstrip revenue. What revenue the company makes does not translate into returns for investors as most of it's funneled back to the lab to further R&D for the clinics next miracle cure. In short, the company went Public to use "investor's" money in the same way MIT (the institutional inspiration and inventor of NMP technology) uses public funds from taxpayers.. Matritech will continue to be a "non-profit" organization focusing on "research" rather than returns while it uses investors money like a grant from the government. Any thought to the contrary? Marty